NASDAQ:IXHL Incannex Healthcare (IXHL) News Today $1.19 +0.05 (+4.70%) (As of 09:56 AM ET) Add Compare Share Share Today's Range$1.19▼$1.1950-Day Range$1.11▼$1.9452-Week Range$1.03▼$4.87Volume226 shsAverage Volume47,288 shsMarket Capitalization$75.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A HeadlinesProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIncannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023finance.yahoo.com - September 8 at 9:58 AMIncannex to file for US testing of psychedelic drug for anxietymsn.com - August 24 at 10:05 PMIncannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GADfinance.yahoo.com - August 24 at 12:04 PMIncannex preparing psilocybin therapy FDA IND applicationproactiveinvestors.com.au - August 24 at 12:38 AMFDA Approves Clinical Trial Of Incannex's Dronabinol-Based Drug For Obstructive Sleep Apneabenzinga.com - August 22 at 9:50 AMIncannex Healthcare’s Clarion Clinics accepting registrations for psychedelic-assisted therapy treatmentproactiveinvestors.com - August 8 at 8:09 AMClarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Openingfinance.yahoo.com - August 8 at 8:09 AMIncannex Healthcare connects superannuation shareholders with independent advice amid US redomiciliationau.investing.com - August 1 at 1:56 AMIncannex Healthcare: Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritisfinanznachrichten.de - July 27 at 1:29 AMIncannex Completes Positive Pre-IND Meeting With FDA On CBD-Based Drug For Treatment Of Rheumatoid Arthritisbenzinga.com - July 27 at 1:29 AMIncannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritisfinance.yahoo.com - July 27 at 1:29 AMIncannex submits IND to begin testing of cannabinoid sleep apnea drugmsn.com - July 21 at 12:58 PMIncannex Submits IND Application To The FDA For Dronabinol-Based Drug For Obstructive Sleep Apneabenzinga.com - July 21 at 12:58 PMIncannex Healthcare targeting clinical trial for sleep apnoea treatment following milestone FDA meetingproactiveinvestors.com.au - July 20 at 8:07 PMFortrea To Manage Incannex's FDA IND Opening Phase 2/3 Trial Of Its Dronabinol-Based Drug For Obstructive Sleep Apneabenzinga.com - July 18 at 12:01 PMIncannex plans to redomicile to US with sole NASDAQ listing – we look at the arithmeticmsn.com - July 11 at 10:36 PMIncannex CEO talks plans to redomicile to USfinance.yahoo.com - July 11 at 5:36 PMIncannex Healthcare to redomicile from Australia to US, list on Nasdaqseekingalpha.com - July 10 at 3:42 PMIncannex Healthcare gets ethics green light to proceed with trial of asset targeting obstructive sleep apnoeaproactiveinvestors.com - July 5 at 8:29 PMIncannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trialfinance.yahoo.com - June 16 at 8:52 AMResearch Analysts Set Expectations for Incannex Healthcare Limited's FY2023 Earnings (NASDAQ:IXHL)marketbeat.com - June 5 at 1:44 AMIncannex welcomes world-leading psychedelics experts to advisory boardproactiveinvestors.com - June 1 at 2:14 AMWorld Renowned International Psychedelics Experts Join Clarion Clinics Advisory Boardfinance.yahoo.com - May 30 at 8:34 AMPsychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiarymsn.com - May 16 at 6:32 PMIncannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Companyfinance.yahoo.com - May 16 at 8:31 AMIncannex enters a lease for first psychedelic-assisted psychotherapy clinicfinance.yahoo.com - May 5 at 7:53 AMIncannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675Afinance.yahoo.com - May 3 at 9:00 AMHealth Care Accessusnews.com - May 2 at 8:21 PMPsyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & Moremsn.com - May 1 at 11:45 PMIncannex announces final results from Phase 1 Clinical Trial assessing safety and pharmacokinetics of IHL-675Aproactiveinvestors.com - May 1 at 11:45 PMNew Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Marketmsn.com - April 25 at 6:07 PMPharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybinfinance.yahoo.com - April 25 at 8:06 AMIncannex Healthcare appoints QPS to advance nicotine and opioid addiction treatment and Renecann™ products in the US and EUproactiveinvestors.com - April 14 at 12:06 AMIncannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiarybenzinga.com - March 17 at 11:45 AMIncannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Expertsfinance.yahoo.com - March 16 at 12:32 PMPsychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorderbenzinga.com - March 15 at 9:18 PMIncannex Healthcare to cut the ribbon on its first psychedelic-assisted psychotherapy clinic in 2023proactiveinvestors.com - March 15 at 9:18 PMWhy Incannex Healthcare Shares Are Gaining Todayfinance.yahoo.com - March 15 at 4:18 PMInterim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatmentfinance.yahoo.com - March 15 at 8:58 AMIncannex Healthcare interim review of PsiGAD therapy reveals 85% probability of significant benefit to patientsproactiveinvestors.com - March 14 at 10:51 PMmarketbeat.com - March 10 at 6:02 AMIncannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Usefinance.yahoo.com - March 3 at 12:04 PMIncannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trialsbenzinga.com - March 3 at 10:45 AMIncannex Healthcare kicks off Phase 2 rheumatoid arthritis trialproactiveinvestors.com - February 28 at 1:23 AMIncannex Healthcare has a significant opportunity in anxiety treatment: Edison Investment Researchproactiveinvestors.com - January 19 at 11:29 PMIndependent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxietyfinance.yahoo.com - January 18 at 9:10 AMShort Interest in Incannex Healthcare Limited (NASDAQ:IXHL) Decreases By 12.1%marketbeat.com - January 2 at 6:55 AMIncannex Healthcare has cash runway into CY25 following fund-raise: Edison Investment Researchproactiveinvestors.com - December 8 at 1:42 AMIncannex Healthcare discusses A$13 million institutional placementproactiveinvestors.com - December 5 at 9:06 PMIncannex Healthcare beefs up cash position with A$13 million institutional placementproactiveinvestors.com - December 4 at 10:40 PM Get Incannex Healthcare News Delivered to You Automatically Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter. Email Address IXHL Media Mentions By Week IXHL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IXHL News Sentiment▼1.430.69▲Average Medical News Sentiment IXHL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IXHL Articles This Week▼21▲IXHL Articles Average Week Get Incannex Healthcare News Delivered to You Automatically Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HCW Biologics News Eliem Therapeutics News SCYNEXIS News Werewolf Therapeutics News Corvus Pharmaceuticals News ADC Therapeutics News Veru News DURECT News Kronos Bio News Zynerba Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:IXHL) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incannex Healthcare Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.